{Reference Type}: Letter
{Title}: [Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation].
{Author}: Houdou L;Kiavué N;
{Journal}: Bull Cancer
{Volume}: 111
{Issue}: 7
{Year}: 2024 Jul-Aug 13
{Factor}: 1.318
{DOI}: 10.1016/j.bulcan.2024.03.005